posted on 2022-05-09, 13:40authored byMary L. Johnson, Richard M. Bergenstal, Brian L. Levy, Darlene M. Dreon
Numerous
studies have shown that early initiation of intensive treatment significantly
improves β-cell function and long-term glycemic control in individuals with
type 2 diabetes (1–4). However, despite national and international clinical guidelines
that recommend escalation of therapy if individualized glycemic targets are not
met within 3–6 months (5), transition to
basal-only insulin therapy and then to intensive insulin management is often
delayed despite significant and sustained hyperglycemia. As reported by Khunti et al. (6), the time to treatment intensification
from noninsulin medications to basal-only insulin therapy is often delayed by
up to 7 years in adults with type 2 diabetes with A1C levels ≥8.0%, and the average time to transition of patients from basal-only insulin to
basal-plus-mealtime insulin is 3.2 years.